Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Conclusion: In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.PMID:38099517 | DOI:10.57264/cer-2023-0142

Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Alexander Russell-Smith Louise Murphy Amy Nguyen Cori Blauer-Peterson Marilou Terpenning Feng Cao Shiqiang Li Tim Bancroft Noah Webb Stephanie Dorman Richa Shah Source Type: research